VMP using weekly and subcutaneous bortezomib is well tolerated and efficacious for newly diagnosed and relapsed myeloma patients

被引：0
|
作者：
O'Sullivan, J. M. [1 ]
Kumar, S. [1 ]
Yeomans, C. [1 ]
Milner, G. [1 ]
Schey, S. [1 ]
Kazmi, M. [1 ]
Streetly, M. J. [1 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2014年 / 165卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
154
引用
收藏
页码：64 / 65
页数：2
相关论文
共 50 条
  • [11] Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen
    Berenson, James R.
    Yellin, Ori
    Woytowitz, Donald
    Flam, Marshall S.
    Cartmell, Alan
    Patel, Ravi
    Duvivier, Herb
    Nassir, Youram
    Eades, Benjamin
    Abaya, Christina DiLauro
    Hilger, Jacqueline
    Swift, Regina A.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 82 (06) : 433 - 439
  • [12] SAFETY AND EFFICACY OF SUBCUTANEOUS VERSUS INTRAVENOUS BORTEZOMIB IN PATIENTS WITH NEWLY ELDERLY DIAGNOSED MULTIPLE MYELOMA
    Bacchiarri, F.
    Nozzoli, C.
    Antonioli, E.
    Staderini, M.
    Barone, F.
    Guarrera, A.
    Messeri, M.
    Coltro, G.
    Grieco, P.
    Bosi, A.
    HAEMATOLOGICA, 2017, 102 : 167 - 167
  • [13] EFFICACY AND SAFETY OF THREE SUBCUTANEOUS BORTEZOMIB COMBINATIONS IN ELDERLY, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Cerrato, C.
    Oliva, S.
    Petrucci, M. T.
    Caraffa, P.
    Nozzoli, C.
    Finsinger, P.
    Larocca, A.
    De Rosa, L.
    De Paoli, L.
    Montefusco, V.
    Saraci, E.
    Villani, O.
    Carella, A. M.
    Benevolo, G.
    Morabito, F.
    Liberati, A. M.
    Derudas, D.
    Boccadoro, M.
    Sonneveld, P.
    Palumbo, A.
    HAEMATOLOGICA, 2014, 99 : 107 - 107
  • [14] Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
    Wu, Shenghao
    Zheng, Cuiping
    Chen, Songyan
    Cai, Xiaoping
    Shi, Yuejian
    Lin, Bijing
    Chen, Yuemiao
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [15] Observational Study Of VMP (Bortezomib), melphalan, prednisolone) Regimen For Newly Diagnosed Korean Myeloma Patients Who Are Not Eligible For Transplantation
    Kim, Kihyun
    Lee, Mark
    Kim, Hyo Jung
    Kim, Yang Soo
    Park, Keon Woo
    Bae, Sung Hwa
    Shin, Ho Jin
    Lee, Won Sik
    Lee, Jung-Hee
    Lee, Jeong Ok
    Yoon, Sung-Soo
    Kim, Ki Hwan
    Nam, Sung-Hyun
    Min, Chang-Ki
    Bae, Sang Byung
    Park, Joon Seong
    Hyun, Myung Soo
    Mun, Yeung-Chul
    Kwak, Jae-Yong
    Lee, Je-Jung
    BLOOD, 2013, 122 (21)
  • [16] VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study
    Dimopoulos, Meletios A.
    Richardson, Paul G.
    Schlag, Rudolf
    Khuageva, Nuriet K.
    Shpilberg, Ofer
    Kastritis, Efstathios
    Kropff, Martin
    Petrucci, Maria T.
    Delforge, Michel
    Alexeeva, Julia
    Schots, Rik
    Masszi, Tamas
    Mateos, Maria-Victoria
    Deraedt, William
    Liu, Kevin
    Cakana, Andrew
    van de Velde, Helgi
    Miguel, Jesus F. San
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : 6086 - 6093
  • [17] Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma
    Ludwig, Heinz
    Kasparu, Hedwig
    Leitgeb, Clemens
    Rauch, Elisabeth
    Linkesch, Werner
    Zojer, Niklas
    Greil, Richard
    Seebacher, Adelheid
    Pour, Ludek
    Weissmann, Adalbert
    Adam, Zdenek
    BLOOD, 2014, 123 (07) : 985 - 991
  • [18] SUBCUTANEOUS BORTEZOMIB CONTAINING REGIMENS AS UPFRONT TREATMENT OF NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
    Rizzello, I.
    Zamagni, E.
    Dozza, L.
    Quaresima, M.
    Petrucci, M. T.
    De Stefano, V.
    Antonioli, E.
    Tosi, P.
    D'Agostino, M.
    Offidani, M.
    Gozzetti, A.
    Rivoli, G.
    Testoni, N.
    Martello, M.
    Tacchetti, P.
    Pantani, L.
    Mancuso, K.
    Rocchi, S.
    Caratozzolo, I.
    Cavo, M.
    HAEMATOLOGICA, 2019, 104 : 117 - 117
  • [19] Bortezomib-Melphalan-Prednisone (VMP) Versus MP as Initial Treatment for Very Elderly Patients With Newly Diagnosed Multiple Myeloma
    Kim, Min Kyoung
    Kim, Kihyun
    Yoon, Do Hyun
    Suh, Cheolwon
    Moon, Joon Ho
    Lee, Yoo Jin
    Lee, Jae Hoon
    Jung, Sung-Hoon
    Lee, Je-Jung
    Kim, Hyo Jung
    Bae, Sung Hwa
    Kim, Jin Seok
    Lee, Jeong-Ok
    Eom, Hyeon Seok
    Lee, Won-Sik
    Kang, Hye Jin
    Mun, Yeung-Chul
    Do, Young Rok
    Hyun, Myung Soo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E70 - E70
  • [20] Cevostamab is efficacious and well tolerated in patients aged < 65 and ≥65 years with relapsed/refractory multiple myeloma (RRMM)
    Krishnan, Amrita
    Cohen, Adam
    Trudel, Suzanne
    Spencer, Andrew
    Lesokhin, Alexander
    Wong, Chihunt
    Choeurng, Voleak
    Cooper, James
    Sumiyoshi, Teiko
    Goodman, Grant
    Jin, Hyun Yong
    Sheikh, Semira
    Harrison, Simon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S42 - S43
12345